Clinical Trial Update: A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years [Phase 3]

View source ↗

Summary

Phase III clinical trial in Chinese women aged 9-45 evaluating an 11-valent recombinant HPV vaccine; the study is currently in recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-related Carcinoma
• Human Papillomavirus Infection

Drugs mentioned

• 11-valent recombinant HPV vaccine (Hansenula polymorpha) (11-valent recombinant human papillomavirus vaccine)

Snippet

Sponsor: National Vaccine and Serum Institute, China | Conditions: HPV InfectioN, HPV-Related Carcinoma | Phase 3 | Status: RECRUITING